Singaporean health tech startup Mesh Bio and UK-based drug discovery firm MultiOmic Health have started collaborating to build a huge multi-omics dataset that will provide insights into metabolic syndrome-related conditions among Asians.
WHAT IT'S ABOUT
According to a press statement, Mesh Bio will tap on its network of healthcare providers to recruit participants for their study, specifically...
